Project Grant HT9425261E107
- Federal Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $624,000 Project Grant award dated July 15, 2025, from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The award supports research to identify mechanisms of tolerance and resistance to darovasertib plus crizotinib in uveal melanoma, with a performance period extending through July 14, 2027. This research addresses critical...
- Federal Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $3.12 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2029. The award supports research and development activities focused on novel tumor-targeted immunotherapies against metastatic uveal melanoma. This research initiative will be conducted at the...
- Federal Project Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $560,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2026, through July 31, 2028. The award supports research titled "Novel Way to Target B-Cell Lymphomas to Reduce Relapse/Refractory Disease," which investigates innovative therapeutic approaches to improve...
- Federal Project Grant Award Summary Thomas Jefferson University (operating as Sidney Kimmel Medical College) received a $1.35 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2030. This four-year award supports identification and evaluation of immune and targeted therapies for acral melanoma, a rare form of melanoma affecting the military and general populations. The...
- The Defense Health Agency awarded a $756,897 Project Grant to Thomas Jefferson University, doing business as the Sidney Kimmel Medical College, for the federal grant program "Military Medical Research and Development" (CFDA 12.420). The grant, effective August 1, 2024 through July 31, 2027, will support "Second-Generation Precision Medicine for BRCA-Mutant Ovarian Cancer" research. Thomas Jefferson University, a leading academic medical center known for its innovative medical...
- Federal Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $819,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2025, with a completion date of April 30, 2028. The award funds research investigating chromium (VI)-driven profibrotic microenvironment and its contribution to lung carcinogenesis, addressing a critical occupational and environmental...
- Federal Project Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $1.1 million Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026, through May 31, 2030. The project, titled "Chemoradiation Imparts KRAS-Mediated Resistance to Immunotherapy in Non-Small Cell Lung Cancer," supports basic and applied biomedical research addressing Service...
- This federal Project Grant award of $858,000.00 from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports a longitudinal analysis of the mesenchymal cell state from melanoma initiation to metastatic progression at Thomas Jefferson University's Sidney Kimmel Medical College. The award, effective August 1, 2024, with a completion date of July 31, 2027, funds advanced biomedical research aimed at transforming healthcare for...
- Federal Grant Award Summary Thomas Jefferson University (operating as Sidney Kimmel Medical College) received a $646,208 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period May 1, 2026 through April 30, 2031. The award supports research investigating spatial heterogeneity of Human Epidermal Growth Factor Receptor 2 (HER2) expression in luminal estrogen receptor-positive (ER+) breast cancer. The project aims to...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University a Project Grant totaling $699,751 under the Military Medical Research and Development program (CFDA 12.420) for the period May 1, 2026 through April 30, 2029. The grant supports research titled "Unveiling Mechanisms and Innovative Therapies for ESR1-CCDC170 Fusions in Clinically Aggressive, Endocrine-Resistant and Metastatic Breast Cancers," to be conducted at the University's facilities in...
Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $1,998,484 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2029. The award funds biomedical research titled "Deciphering the Role of PIK3CA Mutations in Tumorigenesis of HER2-Positive Breast Cancer," with research activities conducted at the institution's Philadelphia, Pennsylvania location. This three-year initiative supports investigator-initiated basic and applied research investigating the molecular mechanisms underlying breast cancer pathogenesis, with findings intended to advance medical solutions relevant to Service Member health and the broader military population. The research program aligns with the DHA's portfolio of cancer biology investigations and leverages Thomas Jefferson University's established infrastructure, including the Sidney Kimmel Cancer Center (an National Cancer Institute-designated comprehensive cancer center) and affiliated research cores. The award supports the institution's ongoing research capability in oncology and translational medicine, contributing to the DHA's strategic objective of transforming healthcare through innovative biomedical research addressing conditions affecting military service members and the American public.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.0m | 5/20/26 |